These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 36652192)

  • 1. Use of Levosimendan in Patients with Pulmonary Hypertension: What is the Current Evidence?
    Masarone D; Kittleson M; Pollesello P; Tedford RJ; Pacileo G
    Drugs; 2023 Feb; 83(3):195-201. PubMed ID: 36652192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levosimendan in two neonates with ischemic heart failure and pulmonary hypertension.
    De Carolis MP; Piastra M; Bersani I; Pardeo M; Stival E; Tempera A; Romagnoli C; Conti G; De Rosa G
    Neonatology; 2012; 101(3):201-5. PubMed ID: 22067520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levosimendan and pulmonary hypertension.
    Cavusoglu Y; Beyaztas A; Birdane A; Ata N
    J Cardiovasc Med (Hagerstown); 2010 Jul; 11(7):478-80. PubMed ID: 20516805
    [No Abstract]   [Full Text] [Related]  

  • 4. Levosimendan and severe pulmonary hypertension during open heart surgery.
    Cicekcioglu F; Parlar AI; Ersoy O; Yay K; Hijazi A; Katircioglu SF
    Gen Thorac Cardiovasc Surg; 2008 Nov; 56(11):563-5. PubMed ID: 19002758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects.
    Pathak A; Lebrin M; Vaccaro A; Senard JM; Despas F
    J Clin Pharm Ther; 2013 Oct; 38(5):341-9. PubMed ID: 23594161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure.
    Kivikko M; Lehtonen L
    Curr Pharm Des; 2005; 11(4):435-55. PubMed ID: 15725064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levosimendan: a new era for inodilator therapy for heart failure?
    Cleland JG; McGowan J
    Curr Opin Cardiol; 2002 May; 17(3):257-65. PubMed ID: 12015475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levosimendan: a novel agent in heart failure.
    Koumallos N; Antoniades C; Tousoulis D; Shirodaria C; Stefanadis C
    Recent Pat Cardiovasc Drug Discov; 2006 Jun; 1(2):185-91. PubMed ID: 18221085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levosimendan is not effective in reducing pulmonary pressures in patients with idiopathic pulmonary arterial hypertension: report of two cases.
    Cavusoglu Y; Beyaztas A; Birdane A; Ata N
    J Cardiovasc Med (Hagerstown); 2009 Jun; 10(6):503-7. PubMed ID: 19346968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levosimendan: A promising agent for the treatment of hospitalized patients with decompensated heart failure.
    Lehtonen L
    Curr Cardiol Rep; 2000 May; 2(3):233-43. PubMed ID: 10980898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of levosimendan in comparison and in combination with dobutamine in the treatment of decompensated heart failure.
    Cavusoglu Y
    Expert Opin Pharmacother; 2007 Apr; 8(5):665-77. PubMed ID: 17376021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Review on Role of the Calcium Sensitive Inotropic Agent, Levosimendan and Its Metabolites.
    Asif M
    Mini Rev Med Chem; 2018; 18(16):1354-1362. PubMed ID: 27594341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levosimendan: beyond its simple inotropic effect in heart failure.
    Antoniades C; Tousoulis D; Koumallos N; Marinou K; Stefanadis C
    Pharmacol Ther; 2007 May; 114(2):184-97. PubMed ID: 17363065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levosimendan is superior to dobutamine as an inodilator in the treatment of pulmonary hypertension for children undergoing cardiac surgery.
    Ebade AA; Khalil MA; Mohamed AK
    J Anesth; 2013 Jun; 27(3):334-9. PubMed ID: 23223915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levosimendan, a new inotropic and vasodilator agent.
    Toller WG; Stranz C
    Anesthesiology; 2006 Mar; 104(3):556-69. PubMed ID: 16508404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levosimendan attenuates pulmonary vascular remodeling.
    Revermann M; Schloss M; Mieth A; Babelova A; Schröder K; Neofitidou S; Buerkl J; Kirschning T; Schermuly RT; Hofstetter C; Brandes RP
    Intensive Care Med; 2011 Aug; 37(8):1368-77. PubMed ID: 21626431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of levosimendan, a novel inotropic calcium-sensitizing drug, in experimental septic shock.
    Oldner A; Konrad D; Weitzberg E; Rudehill A; Rossi P; Wanecek M
    Crit Care Med; 2001 Nov; 29(11):2185-93. PubMed ID: 11700420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tricuspid valve replacement and levosimendan.
    Cicekcioglu F; Parlar AI; Altinay L; Yay K; Katircioglu SF
    Gen Thorac Cardiovasc Surg; 2008 Nov; 56(11):559-62. PubMed ID: 19002757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional and antiischaemic effects of the phosphodiesterase inhibitor levosimendan in isolated rabbit hearts.
    Rump AF; Acar D; Rösen R; Klaus W
    Pharmacol Toxicol; 1994; 74(4-5):244-8. PubMed ID: 8090694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome.
    Uhlig K; Efremov L; Tongers J; Frantz S; Mikolajczyk R; Sedding D; Schumann J
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD009669. PubMed ID: 33152122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.